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 Introduction 
 Th e Nurse’s Healthy Study has reported an association between 
aspirin use and a decrease in distant recurrence and improved 
survival in women with breast cancer who had survived a 
minimum of 1 year following cancer diagnosis. 1 Th is most recent 
report adds to a growing literature suggesting a potential benefi t 
for aspirin use in the prevention of breast cancer. 2–7 Aspirin’s 
clinical benefi t in patients with cancer has been linked in part 
to inhibition of cyclooxygenase in tumor cells. 8,9 Laboratory 
evidence also suggests aspirin decreases tumor angiogenesis and 
vascular endothelial growth factor (VEGF) levels, a protein found 
largely in platelets and a potent stimulator of angiogenesis. 10–13 
 In addition to direct tumor and tissue eff ects, aspirin also 
moderates agonist stimulated platelet activation. Th e platelet 
serves as a reservoir for proangiogenic proteins, such as VEGF, 
and antiangiogenic proteins, such as thrombospondin-1 (TSP-1), 
which can be released from platelets following activation. 14,15 In the 
laboratory, platelet inhibition by aspirin has been demonstrated 
to reduce agonist stimulated VEGF and TSP-1 release from the 
platelet alpha granule suggesting a plausible mechanism by which 
local angiogenic protein levels might be controlled in the tumor 
vasculature micro-environment in aspirin users. 16 In laboratory 
models, platelet inhibition by aspirin and thienopyridine 
derivatives has been demonstrated to decrease angiogenesis, 
further supporting the suppression of platelet activation as a 
viable mechanism of infl uencing tumor angiogenesis. 17 
 We have previously demonstrated that the selective endocrine 
receptor modulators tamoxifen and aromatase inhibitors (AIs; 
anastrozole, letrozole, and exemestane) have diff erential eff ects 
on serum angiogenic protein levels. 18 In that study, tamoxifen use 
was associated with an increase in serum VEGF levels; a result 
consistent with higher platelet derived VEGF levels in tamoxifen 
users as compared to nonusers. 19 Th erefore, women receiving 
tamoxifen therapy might be hypothesized to derive particular 
benefi t from aspirin associated changes in circulating angiogenic 
proteins. Th us, we prospectively studied the impact of aspirin 
therapy on circulating levels of the proangiogenic protein, VEGF, 
and the antiangiogenic protein, TSP-1, as well as platelet mediated 
angiogenic protein release. 
 Materials and Methods 
 Twelve women with a diagnosis of breast cancer (Stage I–IV) or 
DCIS who were current users of tamoxifen therapy for a minimum 
of 90 days were enrolled in this single center study. To minimize 
potential confounding eff ects of prior therapy, a predefi ned interval 
of a minimum of 30 days since the last chemotherapy, radiation 
therapy or surgery was required prior to study enrollment. Current 
users of aspirin, antiplatelet or anticoagulation therapy were 
excluded from enrollment. Intermittent aspirin or nonsteroidal 
antiinfl ammatory (NSAID) users who were willing to abstain 
from periodic use for the duration of the study were enrolled. All 
study participants were queried as to their intake of prescription 
and over the counter medications as well as dietary supplements 
at each study visit. Tylenol use was allowed during the study, and 
no restrictions on dietary supplements were imposed . 
 Patients with a history of prior gastrointestinal or central 
nervous system bleeding or a recent (within 12 months) history 
of any clinically signifi cant bleeding were excluded from the 
study. Patients receiving investigational agents for the treatment 
of breast cancer, with the exception of a gonadotropic releasing 
hormone (GnRH) antagonist, were not included in the study. 
 Patients received study vials containing noncoated 
acetylsalicylic acid (aspirin) 325 mg tabs at initiation of the study 
and following informed consent. Participants were instructed 
to take one aspirin daily for a total of 45 days. Study medication 
compliance was obtained by verbal report and patient interview 
at follow up visits. All adverse events reported by the patient 
during the duration of the study were recorded. 
 Th e study was approved by the institutional review board of 
University of Vermont and written informed consent meeting 
all federal, state and institutional guidelines was obtained from 
all patients. A local, study independent, data safety monitor was 
established prior to clinical study initiation. Th is clinical study 
is registered at clinicaltrials.gov (NCT00727948). 
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 Blood sample collection 
 Venous blood samples were collected prior to initiation of aspirin 
therapy, at 30 and 45 days on-therapy, and 30 days postaspirin 
completion. Plasma samples were collected into vacutainer 
tubes supplemented with 0.5 mL of 3.2% sodium citrate (for 
plasma). Plasma samples were mixed for 30 seconds, separated 
by centrifugation (3,000 rcf for 10 minutes at room temperature 
[RT]) and stored at –80°C. Serum samples were incubated at RT 
for 45 minutes, centrifuged at 2,000 rcf for 15 minutes, and stored 
at –80°C. Standardized sample collection was used for all subjects 
to minimize platelet activation during phlebotomy. 
 Ex vivo platelet activation 
 Venous blood was collected into silicon-coated vacutainers 
containing 0.5 mL of 3.2% buff ered sodium citrate (Becton, 
Dickinson and Company, Franklin Lakes, NJ, USA ). Immediately 
following venipuncture, the blood was treated with 25  μ M (fi nal) 
thrombin receptor activating peptide (TRAP; SFLLRNPNDKYEPF, 
also referred to as TRAP14; Bachem Americas, Torrance, CA, 
USA ) in HEPES-Tyrode’s buff er (5 mM HEPES, 137 mM NaCl, 
2.7 mM NaHCO 3 , 0.36 mM NaH 2 PO 4 , 2 mM CaCl 2 , and 5 mM 
dextrose, pH 7.4), mixed for 30 seconds at RT, and centrifuged 
at 2,000 rcf for 15 minutes (30,000  g -minutes) at RT within 10 
minutes of collection. Plasma was collected and stored at –80°C. 
 Enzyme immunoassay 
 VEGF and TSP-1 levels were measured with a quantitative 
sandwich enzyme immunoassay (Quantikine human VEGF 
kit, Quantikine human Endostatin Kit, R&D Systems, Inc. 
Minneapolis, MN, USA) according to the manufacturer’s 
instructions. All measurements were performed in duplicate and 
the average value reported for each patient at each time point. 
 Statistical analysis 
 Data are presented as mean ± SEM. Repeated measures analysis 
of variance was used to compare means among the 4 time points. 
A signifi cant  F -test was followed by all possible pairwise  t -tests. 
Th e quadratic eff ect was used to examine the eff ect of aspirin 
on the release of angiogenic proteins from platelets prior to and 
posttherapy compared to during aspirin therapy. Th e analyses 
were conducted using SAS (Version 9.2, SAS Institute Inc., Cary, 
NC, USA). Statistical signifi cance was based on  α = 0.05. Reported 
intraplatelet levels of protein were calculated by subtracting 
plasma values from serum values at a given (each) time point. 
 Results 
 Th e characteristics of the women initiating aspirin therapy are 
seen in Table  1 . Th e majority of women had DCIS or stage 1 
invasive ductal carcinoma. Only one patient had metastatic 
disease and was being treated in the nonadjuvant setting. Smoking 
status was assessed but subsequent analysis found no diff erences 
between smokers and nonsmokers in any of the parameters 
measured. Th e average duration of prior tamoxifen use was 
14 months (range 2–46 months). Eleven women completed the 
study with one patient lost to follow-up at 30 days postaspirin 
treatment. No diff erences in platelet counts were observed over 
time ( p = 0.98). Adverse events were reported in two patients 
and included dyspepsia and increased bruising. Both events were 
considered minor and did not preclude completion of the study. 
All women reported continued compliance with aspirin intake 
throughout the study although fi ve women (58%) reported missing 
one to three doses of aspirin at some time during the 45 days 
of treatment. During the 30-day postaspirin study period, no 
participants reported using NSAID therapy. 
 Th e eff ect of aspirin on intraplatelet VEGF and TSP-1 levels 
 Repeated measures analysis of variance detected signifi cant 
diff erences over time in mean intraplatelet TSP-1 and VEGF 
( p value = 0.01 and 0.02, respectively) when analyzed for the 
total study period (four time points). As seen in  Figure  1 , TSP-
1 but not VEGF levels increased following the start of aspirin 
therapy. TSP-1 levels were signifi cantly greater than pretreatment 
following 45 days of aspirin therapy. Th e initial increase in TSP-1 
levels represented a mean 1.3-fold increase in intraplatelet levels. 
 In contrast, aft er completing a 45-day course of aspirin 
therapy, 30-day postaspirin levels of VEGF were signifi cantly 
less than prior to treatment (Table  2 ). VEGF was 21% lower than 
the mean pretreatment level. Mean TSP-1 at 30 days postaspirin 
therapy returned to pretreatment levels and was not signifi cantly 
less than prior to treatment. 
 Th e eff ect of aspirin on serum VEGF and TSP-1 levels 
 Th e impact of daily aspirin therapy on serum protein levels is 
seen in  Figure  1 . Repeated measures analysis of variance detected 
diff erences over time in the mean serum levels of TSP-1 and VEGF 
( p value = 0.01 and 0.02, respectively). TSP-1 increased during 
aspirin therapy and was signifi cantly higher at 45 days when 
compared to pretherapy, with a 33.7% increase in serum TSP-1 
levels. In contrast, no signifi cant changes in VEGF were found 
between mean pretreatment level and mean levels during aspirin 
  N Percent 
Age 
 40–50 3 25 
 50–60 7 58 
 60–70 2 17 
Sex 
 Female 12 100 
Disease stage 
 DCIS 5 42 
 I 4 33 
 II 2 17 
 III 0 0 
 IV 1 8 
Duration of tamoxifen therapy 
 <3 months 1 8 
 >3 months 11 92 
 Prior chemotherapy 4 33 
 Smoking 
 Former 4 33 
 Active 0 0 
 Never 8 67 
 Other malignancies 0 0 
 Table 1.  Characteristics of patients included in the study. 
388 VOLUME 6 • ISSUE 5 WWW.CTSJOURNAL.COM
Holmes et al. ■ Aspirin Modifi es Platelet Angiogenic Proteins
therapy. Th irty days following completion of aspirin therapy, 
VEGF levels were significantly decreased by 21% (Table  2 ). 
Like intraplatelet levels, serum TSP-1 levels following a course 
of aspirin therapy were not diff erent from pretreatment levels. 
 Plasma VEGF and TSP-1 levels aft er aspirin therapy initiation 
 Plasma VEGF and TSP-1 levels were also assessed prior to, during 
and subsequent to daily aspirin therapy. We did not detect any 
signifi cant diff erence over time in VEGF or TSP-1 levels ( p = 0.11 and 
0.44, respectively).  Figure  1 contrasts the plasma levels with serum 
and intraplatelet protein levels following aspirin therapy initiation. 
 Aspirin therapy decreases activation dependent angiogenic 
protein release 
 Because thrombin is considered a major driver of thrombosis 
and platelet activation in tumors, thrombin receptor stimulated 
release of angiogenic proteins was studied in an  ex vivo platelet 
activation whole blood assay ( Figure  2 ). Analysis of released 
TSP-1 and VEGF revealed signifi cant diff erences over time in 
mean TSP-1 release ( p = 0.01). A trend toward inhibition of VEGF 
release was also demonstrated ( p = 0.07). Maximal inhibition 
of thrombin receptor-mediated release was noted at 45 days on 
aspirin therapy. At 45 days on therapy, mean VEGF release was 
decreased by 11% while TSP-1 was decreased by 14%. 
 Discussion 
 We prospectively demonstrated the impact of a short course of 
aspirin therapy on circulating angiogenic protein levels in women 
receiving tamoxifen therapy. Based on two pivotal proteins that 
contribute to the angiogenesis balance, we found aspirin therapy 
has time and protein specifi c eff ects on circulating protein levels. 
Th e majority of our study population was receiving tamoxifen 
in the nonmetastatic setting suggesting our results are likely of 
most relevance to that patient group. Our fi ndings suggest that 
aspirin modulates circulating angiogenic proteins and may favor 
a systemic antiangiogenic balance. 
 Figure 1.  Angiogenic protein levels following the initiation of aspirin therapy. Participants received 325 mg aspirin therapy daily following an initial blood draw. Intraplatelet, 
serum, and plasma levels of VEGF and TSP-1 were subsequently measured by solid phase ELISA at the following time points: (1) prior to aspirin therapy, (2) 30 days on 
aspirin therapy, (3) 45 days on aspirin therapy. Data labels indicate mean values with error bars indicating SEM. 
 VEGF (pg/mL) TSP-1 (ng/mL) 
 Pre Post Pre Post 
Intraplatelet 450.3 (73.2) 355.4 1 (61.7) 7737.5 (969.3) 6234.6 (986.3) 
Plasma 34.2 (4.8) 29.2 (3.2) 279.8 (53.0) 243.6 (65.5) 
 (±SEM).  * Denotes a signifi cant ( p < 0.05) change in protein levels postaspirin therapy. 
 Table 2.  Levels of VEGF and TSP-1 prior to and 30 days after completion of aspirin therapy. Aspirin (325 mg) was initiated in women receiving a stable dose of tamoxifen 
therapy. Following a total duration of 45 days of aspirin therapy, platelet and plasma levels of VEGF and TSP-1 were measured using solid phase ELISA. Values represent mean. 
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 For the antiangiogenic protein TSP-1, the initiation of 
aspirin therapy resulted in signifi cant increases in platelet and 
serum levels. TSP-1 is an antiangiogenic protein stored within 
the platelet alpha granule and platelet (but not plasma) levels 
of TSP-1 have been demonstrated to regulate early stages of 
tumor angiogenesis. 20 Importantly, plasma levels of this protein 
were not found to change in our study. Th e increase in TSP-1 
seen in our study, however, was dependent on the presence of 
drug (aspirin) as posttreatment levels were not diff erent from 
pretreatment levels. Th is observation suggests that aspirin 
treatment may shift  the angiogenic balance by favoring an 
increase in the antiangiogenic protein TSP-1. Th e mechanism 
that underpins this observation will need further assessment 
in subsequent studies. 
 In contrast to TSP-1, VEGF values did not change while 
on aspirin therapy, however, platelet VEGF levels decreased 
following the completion of 45 days of aspirin. VEGF is a potent 
proangiogenic growth factor that has been associated with 
poor prognosis in patients with breast cancer and serum VEGF 
levels correlate with intratumoral microvessel density. 21–23 Th e 
magnitude of the decrease in platelet VEGF that was seen in our 
study was approximately 20%. While we are aware of no conclusive 
data with regard to the degree of decrease needed in circulating 
VEGF to have a clinically significant impact, Banerjee and 
colleagues have found tamoxifen use was associated with a 30% 
increase in VEGF levels. 24 Th us, the magnitude of our eff ect is at 
least consistent with other documented eff ects of drugs on VEGF 
levels in patients. Th e mechanisms that underpin our fi ndings are 
not known. Decreased prostaglandin production (as seen with 
aspirin therapy) has been linked to decreased levels of VEGF. 25 
In addition, in rat models of mammary carcinogenesis, 
acetylsalicylic acid decreased both VEGF concentration and 
tumor diameter. 11  In vitro studies of lung cancer, sarcoma, and 
colon cancer models showed similar results. 12,26 
 A lack of an early decrease in VEGF levels was surprising 
based on the above data. Th e reasons for the delay in response that 
was seen in our study are not known. Th e timing of inhibition of 
tissue production of VEGF relative to aspirin therapy initiation 
is not known. Longer duration of aspirin use and a larger sample 
size will need to be explored in subsequent prospective studies 
using aspirin in cancer patients. 
 Unique to our study is the assessment of the effect of 
aspirin on agonist-induced platelet protein release. Several 
model systems have demonstrated the proangiogenic eff ects 
of platelets (reviewed by Bambace and 
Holmes 27 ). Platelets can contribute to the 
balance of tumor-associated angiogenesis 
through release of both stimulators and 
inhibitors of angiogenesis. 15,28,29 We found 
the release of both angiogenic proteins 
studied was inhibited by aspirin therapy, 
however this result was only signifi cant for 
the antiangiogenic protein, TSP-1. Similarly, 
Coppinger reported in a mass spectrometry 
based analysis of platelet protein release, the 
inhibition of TRAP induced TSP-1 release 
in healthy individuals. 16 Additionally, aspirin 
has been shown to inhibit VEGF release 
from resting platelets as well as platelets 
exposed to ADP and MCF-7 cells. 30 In our 
study, the inhibition of release was modest 
as anticipated given the use of a direct thrombin receptor agonist 
(TRAP) that preferentially (but not exclusively) activates through 
the PAR1 pathway. Th e decrease in release of these angiogenic 
proteins suggests the need for additional platelet pathway specifi c 
investigations in patients with cancer. 
 Limitations of our study include the study of only a subset 
of potential protein contributors to angiogenesis, the short 
course of aspirin therapy and small sample size. We chose to 
initially study early effects of the drug to avoid confounding by 
changes in underlying disease state. A dose-dependent effect 
of aspirin on angiogenic protein levels is also not known. We 
chose an aspirin dose of 325 mg daily based on observational 
data suggesting that 325 mg of aspirin might be necessary 
to achieve maximum chemopreventative effect. 31 In breast 
cancer, the benefits of any particular aspirin regimen (dose 
or duration) are not well established. Additional studies of 
longer duration that include concurrent tissue assessment of 
angiogenesis will be needed to further extend our observations. 
Whether or not the changes we have seen in angiogenic protein 
levels will ultimately be the most important protein specific 
effects of aspirin relative to angiogenesis remains unknown 
at this time. 
 Our data suggests aspirin therapy impacts angiogenic 
protein levels and may modify the angiogenic balance in 
women treated with tamoxifen therapy. The increase in anti-
angiogenic protein levels (TSP-1) while taking aspirin therapy 
without a concurrent increase in pro-angiogenic VEGF levels 
suggests this impact may be, on balance, antiangiogenic. These 
observations are likely most clinically relevant in the primary 
and secondary prevention setting for women with breast cancer 
(including DCIS) receiving tamoxifen therapy. Given the small 
size of our study, additional studies are imperative to fully 
understand the impact of aspirin therapy on angiogenesis 
in patients with breast cancer. Our results should be viewed 
as only a first step in understanding the impact of aspirin 
therapy on the angiogenic balance and important angiogenic 
proteins. However, our data in combination with the observed 
decrease in cancer recurrence in aspirin users in observational 
clinical trials continues to support a role for investigating 
less expensive agents such as aspirin therapy in women with 
breast cancer. 
 Confl ict of Interest 
 Th e authors have no confl ict of interest to declare. 
 Figure 2.  The impact of aspirin therapy on thrombin receptor-mediated release of angiogenic proteins. Patients 
initiated 325 mg of aspirin therapy daily for duration of 45 days. An  ex vivo assay of thrombin receptor agonist 
peptide (TRAP) mediated release was used to determine the impact of aspirin therapy on protein release. Angio-
genic protein levels were measured by ELISA (1) prior to aspirin therapy; (2) 30 days on aspirin therapy; (3) 45 
days on aspirin therapy; and (4) 30 days postaspirin therapy. Data labels represent mean protein values ±SEM. 
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